MARKET WIRE NEWS
  1. Home
  2. Stock
  3. GPCR
  4. News
  5. Structure Therapeutics Glp 1 Agonist Could Be A Pote
GPCR
Quote
Short
News
Articles
Message Board

Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target

Source: SeekingAlpha

2026-03-17 07:45:31 ET

Thesis

Read the full article on Seeking Alpha

For further details see:

Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target
Structure Therapeutics Inc.

NASDAQ: GPCR

GPCR Trading

1.1% G/L:

$48.25 Last:

220,611 Volume:

$48.83 Open:

mwn-link-x Ad 300

GPCR Latest News

March 22, 2026 04:26:16 pm
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
March 17, 2026 12:15:09 pm
Outperform Recommendation Issued On GPCR By BMO Capital
March 16, 2026 02:15:03 pm
Outperform Recommendation Issued On GPCR By William Blair
March 16, 2026 07:00:00 am
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

GPCR Stock Data

$5,430,883,453
65,267,397
0.07%
67
N/A
Biotechnology & Life Sciences
Healthcare
www.structuretx.com
US
South San Francisco

Subscribe to Our Newsletter

Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.

Link Market Wire News to Your X Account

Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.

Download The Market Wire News App

Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.

Market Wire News iPhone App Market Wire News Android App